Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914873 | 0.86 | PTGES (0.53) | SLC15A1ALDH1A1TSHRALOX5MEN1 | |
| SCHEMBL8313296 | 0.84 | CPA1 (0.62) | SLC15A1 | |
| SCHEMBL18065683 | 0.84 | F2 (0.54) | F2F10SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6526152 | 0.83 | SMN1; SMN2 (0.56) | F2F10SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL18065697 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRMEN1NPC1KMT2A | |
| SCHEMBL8903673 | 0.82 | F2 (0.55) | F2F10SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7328942 | 0.82 | F2 (0.52) | F2F10SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2311407 | 0.82 | F2 (0.55) | F2F10SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8216830 | 0.81 | SLC15A1 (0.43) | SLC15A1 | |
| SCHEMBL8216832 | 0.81 | SLC15A1 (0.43) | SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | F2 27/4885F10 20/4885SMN1; SMN2 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.